	monsanto mtc unit sees operating loss in monsanto corp s g d searle and co unit said it will report an operating loss for mainly due to expenses for research and development searle chairman sheldon gilgore said searle s operating loss in will be less than the mln dlr operating loss in he said searle s first quarter sales will be up pct to mln dlrs from mln dlrs in the year ago quarter in searle s sales were mln dlrs gilgore said the company intends to have sales of three billion dlrs by the mid s he said the company anticipates approval in japan the u s italy spain and the u k for its ulcer treatment drug cytotech he also said that in a paper not yet published the drug was shown to prevent a flare up of ulcers for a longer period of time than tagamet made by smithkline beckman corp skb other drugs in searle s pipeline include tissue plasminogen activator tpa made by a different process than genentech s gene tpa expected to be approved for marketing this year reuter 
